Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An announcement from Zylox-Tonbridge Medical Technology Co., Ltd. Class H ( (HK:2190) ) is now available.
Zylox-Tonbridge Medical Technology Co., Ltd., a PRC-incorporated medical technology company listed in Hong Kong, is updating its corporate governance framework to reflect changes in PRC company law and overseas listing rules. The firm remains governed by a board that includes executive, non-executive and independent non-executive directors, underlining a standard listed-company oversight structure.
The board has proposed cancelling the company’s Supervisory Committee and transferring its oversight powers to the board’s Audit Committee through amendments to the articles of association, to be voted on at the 2025 annual general meeting. These changes, which will take effect only if approved by shareholders, are intended to streamline governance in line with updated regulatory guidelines, with the existing supervisory body continuing to operate until the new framework is formally adopted.
If the amendments are approved, the revised articles will be published on both the company’s and the Hong Kong Stock Exchange’s websites, providing shareholders and investors with clarity on the new governance arrangements. The board believes the overhaul is in the best interests of the company and its shareholders, signalling a move towards a more modern, audit-committee-centric oversight model consistent with current corporate governance standards for listed companies.
The most recent analyst rating on (HK:2190) stock is a Hold with a HK$28.00 price target. To see the full list of analyst forecasts on Zylox-Tonbridge Medical Technology Co., Ltd. Class H stock, see the HK:2190 Stock Forecast page.
More about Zylox-Tonbridge Medical Technology Co., Ltd. Class H
Zylox-Tonbridge Medical Technology Co., Ltd. is a People’s Republic of China-based medical technology company listed in Hong Kong under stock code 2190. It operates in the healthcare and medical devices sector, with its governance structure overseen by a board comprising executive, non-executive and independent non-executive directors, and is subject to PRC company law and Hong Kong listing regulations.
The company focuses on aligning its corporate governance and articles of association with evolving PRC and Hong Kong regulatory requirements, indicating an emphasis on compliant operations and transparent oversight for its shareholders.
Average Trading Volume: 700,433
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.31B
Find detailed analytics on 2190 stock on TipRanks’ Stock Analysis page.